Clinical Results for ACT®

Clinical Results for Patients with Type II and Type III Stress Incontinence

ACT Therapy has been used in more than 1,200 women in Europe, Canada, South America and Australia. It is currently being studied in the United States in a Food and Drug Administration clinical study. Results of a previous study (49 patients) suggest that after six months, 65% of patients were dry and another 16% were much improved [Figure 1].¹

Figure 1. Overall Impression

40-month follow up after implant. 65.3% reported as dry.

The potential risks with the ACT implant procedure are similar to those for other surgical treatments for stress urinary incontinence. These include, but are not limited, to the following:

Tissue perforation (tear)
Device migration
Tissue erosion/infection at the implant site
Device failure
Non-response to treatment
Post-operative urgency, frequency, or retention

If an infection occurs at the implant site, it can be treated with antibiotics. If the device migrates, changes can be made to improve the positioning. If a more serious side effect occurs (e.g., perforation, migration), ACT can be completely removed. Please ask your doctor any questions you may have about the procedure.

Important Safety Information About ACT

Contact Uromedica to learn more about how ACT Therapy may meet your individual needs.

Footnotes

¹ Kocjancic E, et al. Adjustable continence therapy as a surgical treatment for recurrent female urodynamic stress urinary incontinence [abstract]. Taken from: American Urological Association (Anaheim). 2007;1461.

—This page last modified Thursday July 31, 2008